Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as Beimei Pharm) and Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as ASK Pharm) announced the strategic cooperation. Both parties will integrate the superior resources to jointly promote innovation and research and development of pediatric prescription drugs and solve unmet clinical needs in China, with a view to initiating in-depth cooperation in R&D transformation, manufacturing, sales promotion and equity cooperation.

Both parties will promote multi-level and multi-dimensional R&D technical cooperation, and actively promote the creation of special dosage forms for children and precision drug administration research with the opportunity of characteristic technical development and clinical expansion of some products. Both sides will focus on the digestion and anti-infection areas to focus on the strength of complementary resources, create a series of pediatric medicine brand products. In addition, both parties will make full use of hardware resources such as plant construction and equipment investment to share the benefits brought by high-efficiency production quality management and scale cost control to achieve high-quality and sustainable development.

Ms. Wu Guangmei, Chairman and CEO of Beimei Pharm, said: "We are very pleased to reach strategic cooperation with ASK Pharm. In this cooperation, Beimei Pharm will give full play to the advantages of product layout in the field of pediatric medicine, and ASK Pharm will give full play to the advantages of market commercialization capability in the key areas. Both sides have complementary advantages, accelerating the development and commercialization of domestic clinical urgent needs and clinical unsatisfied products, and jointly expanding the pediatric medicine market.”

Mr. Ma Jingfei, General Secretary of ASK Pharm, said:” With the gradual inclination of favorable national policies in recent years to encourage the research and development and access of pediatric medicine, the strategic cooperation between the company and Bemei Pharm will be conducive to the realization of efficient synergy of industries and resources between the two parties to jointly expand the pediatric medicine market and meet the clinical needs of the domestic pediatric market.”

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

 Jiangsu Aosaikang Pharmaceutical Co., Ltd. (ASK Pharm) is a wholly-owned subsidiary of Beijing Aosaikang Pharmaceutical Co., Ltd. (Stock code: 002755.SZ), a company listed on the main board of the Shenzhen Stock Exchange, with two technological research and development platforms, namely chemical and biological drugs. It is a comprehensive high-tech enterprise integrating R&D, production and sales. ASK Pharm’s products cover the fields of digestion, anti-tumor, chronic ailment, anti-drug-resistant infection and other treatment, and have a very high brand influence in the market segment. For many consecutive years, he was awarded the honorary title of "Best Industrial Enterprise of China Pharmaceutical R&D Product Line" and "National Innovative Pharmaceutical Enterprise."

Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields. Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated.